Harmony Biosciences (NASDAQ:HRMY – Get Free Report) will be releasing its earnings data before the market opens on Tuesday, October 29th. Analysts expect Harmony Biosciences to post earnings of $0.66 per share for the quarter. Harmony Biosciences has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.24. The business had revenue of $172.80 million during the quarter, compared to analyst estimates of $172.53 million. Harmony Biosciences had a return on equity of 22.97% and a net margin of 17.53%. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.56 earnings per share. On average, analysts expect Harmony Biosciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Harmony Biosciences Trading Up 1.3 %
HRMY opened at $34.50 on Monday. The firm’s 50 day moving average is $36.40 and its 200-day moving average is $32.96. Harmony Biosciences has a 52-week low of $19.03 and a 52-week high of $40.60. The company has a quick ratio of 3.09, a current ratio of 3.13 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $1.96 billion, a P/E ratio of 17.69, a P/E/G ratio of 0.69 and a beta of 0.73.
Analysts Set New Price Targets
Check Out Our Latest Research Report on HRMY
About Harmony Biosciences
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Further Reading
- Five stocks we like better than Harmony Biosciences
- Best Aerospace Stocks Investing
- Amazon: Why Analysts Think It’s A Solid Buy Ahead Of Earnings
- Investing in the High PE Growth Stocks
- NextEra’s Diverse Business Is Set to Win As Energy Demand Rises
- Options Trading – Understanding Strike Price
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.